WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

"Modern techniques in Acute Myelogenous Leukemia: A Review of Current Techniques and Future Directions"

[1)]Miss. Pooja B. Sankpal, [2)]Mr. Omkar Marathe, [3)]Miss. Prachi Choukekar, [4)]Mr. Prasad Yadav, [5)]Dr. Nilesh Chougule

E-Mail – poojasankpal05@gmail.com
Affliation – Undergraduate
E-Mail – maratheomi88@gmail.com
Affliation- Undergraduate
E-Mail – sakharamchaukekar@gmail.com
Affliation - Undergraduate
E-Mail – prasadyadav3912@gmail.com
Affliation- Assistant Professor
E-mail- nlshchougule1008@gmail.com
Affliation - Principal
Ashokrao Mane Institute of Pharmacy, Ambap Kolhapur, Maharashtra, India (416112)

ABSTRACT:

Acute myeloid leukemia (AML) remains one of the most complex and aggressive forms of blood cancer, presenting a unique challenge due to its diverse genetic landscape and unpredictable clinical behavior. In recent years, machine learning (ML) has emerged as a game-changer in the fight against AML, offering unprecedented tools to decode its intricacies. This review dives deep into the transformative potential of ML, from enhancing the precision of diagnosis and refining risk stratification to personalizing treatment plans and predicting patient outcomes. Additionally, we explore cutting-edge breakthroughs in next-generation drug design—leveraging artificial intelligence, structure-based drug discovery, and precision medicine to develop innovative therapies like Venetoclax, Midostaurin, and Ivosidenib. By targeting the molecular abnormalities at the heart of AML, these drugs mark a shift towards more effective, personalized treatments. While challenges such as data quality, model transparency, and ethical concerns remain, the convergence of ML and advanced therapeutic strategies holds the promise of revolutionizing AML management. This new frontier offers a future where patient outcomes are not just improved, but transformed.

Keywords: Acute myeloid leukemia (AML), machine learning (ML), Artificial Intelligence (AI),

Introduction:

Acute myeloid leukemia (AML) remains a formidable challenge in hematology, characterized by its diverse genetic landscape, variable patient responses, and often aggressive clinical course. Machine learning (ML), a subfield of artificial intelligence, offers a powerful tool to address these complexities and improve patient outcomes. This comprehensive review will delve into the current state of ML applications in AML management, exploring its role in diagnosis, risk stratification, treatment selection, prognosis prediction, and beyond.

Understanding AML and its Heterogeneity:

Particularly the clinical description of AML is frequently attributed to Wilhelm Ebstein. Ebstein used the term "acute leukämie" in 1889 to represent a rapidly progressing sickness. This may have been the first instance in which the disease's acute and chronic subtypes were clinically distinguished. Neumann, who was the first to notice that white blood cells are synthesized in the bone marrow, also introduced the word "myeloid." Moreover, Mosler was the first to outline the process of using bone marrow examination to formally diagnose leukemia in the late 1800s. Last but not least, Naegeli, who was in charge of splitting leukemia into lymphocytic and myeloid subtypes, identified the malignant cell in acute myeloid leukemia, known as the myeloblast.

AML is a heterogeneous disease characterized by the uncontrolled proliferation of immature myeloid cells in the bone marrow. This heterogeneity arises from a wide range of genetic mutations and phenotypic variations, contributing to the diverse clinical course and variable responses to treatment. Understanding the underlying biology of AML is crucial for developing effective therapeutic strategies.[1]

Acute Myelogenous Leukemia (AML) Symptoms:

The main symptoms are:

- Pale look and feeling tired and breathless – mostly due to anemia caused by reduction in RBCs.
- Prone to more infection than usual – Due to lack of WBCs.
- Unusual bleeding caused by very few platelets - bruises may appear without any injury, heavy periods in women, bleeding gums, nose bleeds and blood spots or rashes on the skin.
- Feeling Generally Unwell and Run Down.



Fig. 1: Modern approach of ML, AI in AML.

Abbrevations

1. AML- Acute myeloid leukemia
2. ML-Machine Learning
3. RBC-Red Blood Cell
4. WBC-White Blood Cell
5. AI – Artificial Intelligence

Diagnosis and Classification:

- Convolutional Neural Networks (CNNs): CNNs have demonstrated exceptional performance in analyzing bone marrow images, accurately identifying leukemia cells and distinguishing them from normal hematopoietic cells.
- Transfer Learning: Pre-trained CNN models, such as those developed for image recognition tasks in other domains, can be adapted to AML diagnosis, leveraging their existing knowledge.
- Automated Cell Counting: ML algorithms can automate the process of counting leukemia cells in bone marrow smears, reducing the workload for pathologists and improving consistency.
- Cytogenetic and Molecular Analysis:
- Genetic Mutation Identification: ML can accurately identify genetic mutations associated with AML, such as FLT3, NPM1, and CEBPA, using techniques like support vector machines (SVMs) and random forests.
- Fusion Gene Detection: ML can detect fusion genes, such as PML-RARα and BCR-ABL, which are characteristic of certain subtypes of AML.[2]

Risk Stratification

Prognostic Models:

- Survival Prediction: ML algorithms can develop models that predict a patient's overall survival and event-free survival based on a combination of clinical, genetic, and laboratory parameters.
- Relapse Risk Assessment: ML can identify patients at high risk of relapse, allowing for more intensive monitoring and early intervention.

- Treatment Response Prediction: ML can predict a patient's response to specific treatments, guiding treatment decisions and avoiding ineffective therapies.

Personalized Treatment Planning:

- Treatment Algorithm Development: ML can develop algorithms that recommend personalized treatment plans based on a patient's individual characteristics and risk profile.
- Clinical Decision Support Systems: ML-powered systems can assist clinicians in making informed decisions about treatment options, considering factors such as patient preferences, comorbidities, and available resources.[3]

Treatment Selection and Optimization

Drug Response Prediction:

- In Vitro Modeling: ML can analyze in vitro data from drug sensitivity assays to predict a patient's response to specific treatments.
- Clinical Trial Data Analysis: ML can identify patterns in clinical trial data to inform drug selection and combination therapies.

Combination Therapy:

- Synergy Prediction: ML can predict the synergistic effects of drug combinations, optimizing treatment regimens and minimizing adverse events.
- Personalized Combination Therapy: ML can identify the optimal combination of drugs for individual patients based on their genetic profile and tumor characteristics.[4]

Prognosis Prediction

Survival Prediction:

- Long-Term Survival: ML can predict long-term survival outcomes, providing patients and their families with valuable information for planning and decision-making.
- Disease Progression: ML can predict the rate of disease progression, guiding treatment decisions and monitoring for relapse.

Relapse Prediction:

- Early Detection: ML can identify early signs of relapse, allowing for timely intervention and potentially improving outcomes.
- Risk Stratification: ML can stratify patients based on their risk of relapse, guiding the intensity of post-treatment surveillance and follow-up.[5]

Challenges and Opportunities:

While ML offers significant promise for AML management, several challenges need to be addressed:

- Data Quality and Quantity: High-quality, annotated datasets are essential for training ML models. Collecting and curating such data can be challenging, especially for rare diseases like AML. [6,7]
- Model Interpretability: Understanding how ML models make decisions is crucial for clinical adoption and trust. Black-box models can be difficult to interpret, making it challenging to explain their predictions to clinicians and patients. [8]
- Ethical Considerations: Ensuring fairness, bias, and privacy in ML applications is essential. Bias in training data can lead to biased models, which can have negative consequences for patient care. [9]
- Heterogeneity: The genetic and phenotypic diversity of AML complicates the identification of universal therapeutic targets. [10]
- Drug Resistance: The development of resistance to existing therapies is a significant barrier to long-term remission. [11]
- Clinical Trials: Designing effective clinical trials that account for the complexity of AML and its subtypes is crucial for advancing new therapies. [12]

Despite these challenges, the opportunities for ML in AML management are substantial. By addressing these challenges and leveraging the power of ML, we can improve patient outcomes and advance the field of hematology. [13,14]

Future Directions for Research:

- Integration of Multi-omics Data: Combining genomic, transcriptomic, proteomic, and metabolomic data can provide a more comprehensive understanding of AML biology and enable more precise patient stratification and treatment selection.
- Real-world Data Analysis: Analyzing real-world data from clinical trials and routine patient care can help identify patterns and trends that may not be apparent from randomized controlled trials.
- Development of Novel ML Algorithms: Continuously developing new ML algorithms and techniques can improve the performance and interpretability of models.
- Collaboration between Clinicians and Data Scientists: Fostering collaboration between clinicians and data scientists can accelerate the development and implementation of ML-based solutions for AML management.[15]

Target specific approach:

Next-generation drug design for Acute Myelogenous Leukemia (AML) focuses on developing novel therapies that target specific genetic and molecular features of the disease. These innovative approaches aim to overcome the limitations of traditional chemotherapy and address drug resistance, improving efficacy and reducing toxicity. Here's a more focused overview of advances in next-generation drug design in AML:

- **Menin Inhibitors**

Menin is a key protein involved in the regulation of gene expression through interactions with the MLL (Mixed Lineage Leukemia) fusion protein. Mutations in MLL are common in certain subtypes of AML, especially in younger patients. Next-generation menin inhibitors are being designed to target these protein interactions:

- SNDX-5613: This is a menin inhibitor currently in clinical trials for MLL-rearranged AML. The drug works by blocking the menin-MLL fusion interaction, which is critical for the growth of MLL-mutant leukemic cells.
- KO-539: Another menin inhibitor targeting MLL-rearranged and NPM1-mutant AML. By disrupting the menin interaction, these drugs promote differentiation and death of leukemia cells.

These inhibitors represent a promising approach for treating AML subtypes that harbor specific genetic alterations. [16,17,18]

- **NPM1-Targeting Drugs**

Mutations in the NPM1 (Nucleophosmin 1) gene are among the most common in AML. These mutations result in the mislocalization of the NPM1 protein, which plays a critical role in maintaining cellular homeostasis. Drugs targeting NPM1 mutations aim to correct this mislocalization and restore normal cell function:

- NPM1 inhibitors: Researchers are developing small molecules that can bind to mutant NPM1 and relocate it to the nucleolus, which may restore normal function or enhance the susceptibility of AML cells to apoptosis. This area is still in preclinical development, but it holds potential for a highly selective approach to NPM1-mutated AML.[19]

- **Protein Degradation Technologies (PROTACs)**

Proteolysis-targeting chimeras (PROTACs) represent a new class of drugs designed to induce the degradation of disease-causing proteins rather than simply inhibiting their function. In AML, key oncogenic proteins such as FLT3 or mutated transcription factors are prime targets:

- PROTAC molecules can selectively bind to target proteins and recruit the cell's natural degradation machinery (the proteasome), leading to the destruction of the cancer-causing proteins. This approach is particularly attractive for targeting proteins that are difficult to inhibit directly using traditional small molecules.[20]

- **Targeting Transcriptional and Epigenetic Machinery**

AML is often driven by mutations affecting transcription factors or epigenetic regulators. Next-generation drugs are designed to selectively target these altered pathways:

- DOT1L Inhibitors: DOT1L is an enzyme responsible for the methylation of histone H3, and it plays a key role in MLL-rearranged AML. Drugs targeting DOT1L, such as pinometostat (EPZ-5676), inhibit this methyltransferase activity, suppressing the abnormal gene expression driven by the MLL fusion protein.
- Bromodomain and Extra-Terminal Domain (BET) Inhibitors: BET proteins regulate the expression of cancer-promoting genes by binding to acetylated histones. Inhibitors like JQ1 and OTX015 are designed to disrupt this interaction, leading to reduced transcription of oncogenes such as MYC, which are often overexpressed in AML.[21]

- **Targeting Metabolic Pathways**

AML cells often have altered metabolic pathways that allow them to survive and proliferate in nutrient-limited environments. Next-generation drug design is focusing on these unique vulnerabilities:

- Mutant IDH1/IDH2 Inhibitors: IDH mutations result in the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which blocks cellular differentiation. Ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) work by restoring normal metabolic processes, allowing leukemia cells to mature and stop dividing.
- Metabolic Inhibitors: Other drugs are being developed to target key enzymes in AML cell metabolism, such as glutaminase and pyruvate kinase, which are critical for the abnormal metabolic processes in leukemia cells.[22]

- **Novel FLT3 Inhibitors**

The FLT3 gene is mutated in about one-third of AML patients, and this mutation leads to the uncontrolled growth of leukemia cells. While earlier FLT3 inhibitors, like midostaurin and gilteritinib, have shown some success, drug resistance often develops. To overcome this, next-generation FLT3 inhibitors are being designed:

- Quizartinib: A next-generation FLT3 inhibitor that is more selective and potent against the FLT3 mutation, with a better side-effect profile.
- Crenolanib: This drug is being developed to overcome resistance seen in earlier FLT3 inhibitors, showing promise in clinical trials for FLT3-mutated AML.[23]

- **TP53-Targeting Therapies**

Mutations in the TP53 gene, which encodes the tumor suppressor protein p53, are associated with poor prognosis in AML. Targeting this pathway has been a challenge, but next-generation therapies aim to restore or mimic p53 activity:

- APR-246 (Eprenetapopt): A small molecule that reactivates mutant p53, restoring its tumor-suppressing function. This drug is being studied in combination with other therapies to treat TP53-mutated AML.
- MDM2 Inhibitors: MDM2 is a protein that negatively regulates p53. Drugs like idasanutlin are designed to block MDM2, thereby reactivating p53 and promoting cancer cell death.[24]

- **Gene-Editing and CRISPR-based Therapies**

Although still largely in the experimental phase, gene-editing technologies like CRISPR-Cas9 are being explored as potential therapies for AML. These technologies offer the possibility of correcting specific genetic mutations at the DNA level:

- CRISPR-Cas9: Researchers are investigating the use of CRISPR to target and correct oncogenic mutations, such as those in FLT3 or NPM1, or to modify the expression of genes critical to AML survival. While clinical applications are still limited, the potential for precise genetic manipulation holds immense promise for the future of AML treatment.[25]

Next-generation drug design for AML is leveraging cutting-edge technologies like menin inhibitors, PROTACs, epigenetic modulators, metabolic inhibitors, and gene-editing strategies. These novel approaches aim to target the underlying genetic and molecular drivers of AML more precisely and effectively than traditional therapies. As these therapies move through clinical trials, they hold great potential to improve outcomes, particularly for patients with difficult-to-treat forms of AML or those who develop resistance to current treatments.

Overall, these targeted therapies show promising potential for AML patients. The broader and deeper molecular understanding of this disease has paved the way to address the core problems of treatment. However, there are challenges in regards to designing a proper scientific and clinical trial approach to attain the most accurate efficacy of these targeted drugs to deliver fuller benefits to patients. The phenotype of AML disease has been developed as a consequence of complex genetic and biological pathway changes, hence, addressing its complex nature would not be possible with one specific target, whereas a combinatorial approach could potentially include the various facets of this disease. The continuous and determined focus on understanding the underpinnings of molecular genetics and epigenetics, as well as the persistent surveillance of clonal evolution before and after the treatment of these targeted therapies, could potentially introduce novel changes to the treatment strategies, offering the maximum beneficial outcomes to patients of all ages.

Drug discovery methods:

Drug discovery for Acute Myelogenous Leukemia (AML) has greatly benefited from modern design techniques, particularly those involving computational and data-driven approaches. Below are some of the leading techniques in drug discovery for AML and specific drugs developed or being developed using these strategies:

1. Structure-Based Drug Design (SBDD):

- SBDD involves understanding the 3D structure of key proteins or enzymes in AML cells and designing molecules that can effectively target these structures.
- Example: Venetoclax (approved): Venetoclax targets the BCL-2 protein, which is involved in preventing apoptosis (programmed cell death) in cancer cells. By inhibiting BCL-2, Venetoclax promotes the death of AML cells. Its development relied on structural biology to understand the binding sites of BCL-2.[26]

2. High-Throughput Screening (HTS) and Virtual Screening:

- These techniques involve testing large libraries of compounds to find those that have biological activity against AML cell targets. Virtual screening uses computational methods to simulate and prioritize compounds for actual screening, significantly speeding up the process.
- Example: Midostaurin (approved): Midostaurin inhibits FLT3, a receptor tyrosine kinase often mutated in AML. HTS identified Midostaurin as a potent inhibitor of FLT3 and other kinases involved in AML proliferation.[27]

3. Machine Learning and Artificial Intelligence (AI):

- AI-driven approaches analyze vast datasets (genomics, proteomics, drug response data) to identify potential drug candidates and predict how AML cells will respond to specific therapies. AI can also help design molecules with optimized properties for AML treatment.
- Example: AI-driven Drug Design (in development): Several biotech companies are using AI to design new inhibitors of mutated forms of the IDH1 and IDH2 enzymes, commonly seen in AML patients. AI tools are accelerating the identification of molecules that can inhibit these mutations effectively.[28]

4. Fragment-Based Drug Design (FBDD):

- FBDD involves starting with small chemical fragments that bind weakly to the target protein and then "growing" or "linking" them to create more potent inhibitors.
- Example: Ivosidenib (approved): Ivosidenib is an IDH1 inhibitor used for AML patients with IDH1 mutations. FBDD was instrumental in identifying the binding interactions of small fragments with the IDH1 enzyme and optimizing the drug's design to selectively inhibit the mutant form.[29]

5. CRISPR/Cas9 Screening:

- CRISPR/Cas9 genome editing allows for the identification of essential genes and potential drug targets in AML. This technique can pinpoint vulnerabilities in cancer cells that can be targeted by drugs.
- Example: CRISPR-based screens have identified potential therapeutic targets like MLL-rearranged AML (a subset of AML with specific genetic rearrangements). New drugs targeting these vulnerabilities are being explored using CRISPR data.[30]

6. Bi-specific Antibodies and CAR-T Cell Therapy:

- These immunotherapy-based approaches are increasingly being designed using modern bioinformatics tools to enhance their specificity and effectiveness in AML.
- Example: Gemtuzumab ozogamicin (approved): This is a bi-specific antibody-drug conjugate that targets CD33, an antigen expressed on AML cells. It was designed using bioinformatics to link an antibody to a cytotoxic drug for targeted killing of AML cells.[31]

7. Omics and Precision Medicine:

- Genomic and proteomic profiling of AML patients can reveal specific mutations and expression patterns, allowing for the design of precision medicines tailored to individual patients' AML subtypes.
- Example: Enasidenib (approved): This IDH2 inhibitor was developed for AML patients with specific IDH2 mutations. Its discovery was facilitated by genomics studies identifying IDH2 mutations as drivers of AML in a subset of patients.[32]

Conclusion:

AML is a disease of a highly complex nature with a varied genomic landscape with a number of different mutations, and this complexity has presented a challenge to drug development for nearly five decades. However, the recent development of targeted there Apies seeks to resolve this complexity. The main role of targeted therapy is to target the specific abnormality with maximum efficacy. The improved overall survival (OS) rate seen in patients with some of these agents is evidence of positive results that can grant hope to patients, scientists, and physicians. Despite the fact that not all targeted agents were discussed within the contents of this review, we have covered numerous promising agents of interest.

Machine learning has the potential to revolutionize the management of acute myeloid leukemia by improving diagnosis, risk stratification, treatment selection, and prognosis prediction. By addressing the challenges and seizing the opportunities, we can harness the power of ML to improve patient outcomes and advance the field of hematology.

Modern drug discovery techniques such as structure-based design, AI-driven approaches, and precision medicine are making significant contributions to the development of new therapies for AML. Drugs like Venetoclax, Midostaurin, and Ivosidenib demonstrate the success of these methods in targeting the genetic and molecular abnormalities characteristic of AML. With continued advancements in computational methods and personalized medicine, more innovative therapies for AML are likely to emerge.

REFERENCES:

1. Heuser M, Ganser A. Prognostic factors in acute myeloid leukemia. Curr Opin Oncol. 2000;12(1):29-36.
2. Jiang S, Zhang X, Sun L, Wang Z, Han T. Application of convolutional neural networks in the diagnosis of hematological diseases. Front Oncol. 2020;10:610261.
3. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:8-17.
4. Ngai LL, Quek ST, Shen L, Loo E, Guo J, Tan G, et al. Machine learning applications in AML: Use of artificial intelligence for risk stratification and treatment prediction. Hematol Oncol Clin North Am. 2020;34(5):1055-1065.
5. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079-89.
6. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. doi:10.1056/NEJMra1406184.
7. Pollyea DA, Amaya ML, Strati P, Konopleva M. New directions in acute myeloid leukemia: Novel therapies and beyond. Semin Hematol. 2015 Jan;52(1):74-82. doi:10.1053/j.seminhematol.2014.10.007.
8. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018 Jun;562(7728):526-31. doi:10.1038/s41586-018-0623-z.
9. DiNardo CD, Cortes JE. Mutations in AML: Prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):348-55. doi:10.1182/asheducation-2016.1.348.
10. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728-40. doi:10.1056/NEJMoa1902688.
11. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Jun;17(6):721-49. doi:10.6004/jnccn.2019.0028.
12. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018 Jun 9;392(10147):593-606. doi:10.1016/S0140-6736(18)31041-9.
13. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytogenetic and molecular genetic features of acute myeloid leukemia. Blood. 2010;115(1):74-82.
14. Stahl M, Shallis RM, Bewersdorf JP, Halene S, Zeidan AM. Machine learning for outcome prediction in AML: Current applications and future directions. Blood Rev. 2021;47:100789.
15. Anwar SM, Majid M, Qayyum A, Awais M, Alnowami M, Khan MK. Medical image analysis using convolutional neural networks: A review. J Med Syst. 2018;42(11):226.
16. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593-606.
17. Shouval R, Labopin M, Bondi O, Mishan E, Shimoni A, Schmid C, et al. Machine learning algorithms for prediction of outcomes following allogeneic hematopoietic cell transplantation: A retrospective multicenter cohort study. Lancet Haematol. 2021;8(2):e122-34.
18. Weisberg E, Griffin JD. FLT3 inhibition as a targeted therapy for acute myeloid leukemia: a review. Leukemia. 2021;35(12):3124-40. doi:10.1038/s41375-021-01452-9.
19. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722-31. doi:10.1182/blood-2017-04-779405.
20. Krivtsov AV, Armstrong SA. Targeting MLL translocations in MLL-rearranged leukemias. Cancer Cell. 2007;12(3):197-9. doi:10.1016/j.ccr.2007.08.017.
21. DiNardo CD, Stein EM, De Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386-98. doi:10.1056/NEJMoa1716984.
22. Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo CA, Vanden Berghe W, Cuendet M. Epigenetic strategies to target cancer stem cells in acute myeloid leukemia. Cancer Lett. 2021;509:24-37. doi:10.1016/j.canlet.2021.03.029.
23. Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506-25. doi:10.1158/2159-8290.CD-19-1038.

24. Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol. 2016;3(4):e186-95. doi:10.1016/S2352-3026(16)00002-3.
25. Zeidan AM, Knaus HA, Robinson TM, Towlerton AM, Warren EH, Zeiner P, et al. Immunotherapy approaches for acute myeloid leukemia: current status and future directions. Mol Cancer Ther. 2021;20(5):872-84. doi:10.1158/1535-7163.MCT-20-0598.
26. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med*. 2013;19(2):202-8.
27. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. *N Engl J Med.* 2017;377(5):454-64.
28. Zhavoronkov A, Ivanenkov Y, Aliper A, Veselov M, Aladinskiy V, Aliper I, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol*. 2019;37(9):1038-40.
29. Popovici-Muller J, Lemieux RM, Artin E, Saunders JO, Salituro FG, Travins J, et al. Discovery of AG-120 (Ivosidenib): a first-in-class IDH1 mutant inhibitor for the treatment of IDH1 mutant cancers. *ACS Med Chem Lett*. 2018;9(4):300-5.
30. Wang T, Yu H, Hughes NW, Liu B, Kendirli A, Klein K, et al. CRISPR screening identifies essential genes in human AML cells. *Cell Reports*. 2019;27(2):393-404.
31. Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Vignetti M, et al. Gemtuzumab ozogamicin (Mylotarg) as post-remission treatment in acute myeloid leukemia (AML): Results of the EORTC-GIMEMA AML-19 trial. *Blood.* 2005;106(10):3612-20.
32. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. *Blood.* 2017;130(6):722-31.